Research at University Health Network
 
Technology Transfer
Menu Level 3  
   
About UHN Research
 
Welcome from the Executive Vice President

Welcome to University Health Network's Research web site.

Our five research institutes are committed to research with scientific and clinical impact. The proximity of basic researchers and clinician-scientists provides the full spectrum of expertise required to make discoveries in basic, translational and clinical research.

We have launched programs in genomics, proteomics, advanced diagnostics, eHealth, regenerative medicine, cancer informatics, cardiology, transplantation, immunology and autoimmunity, infectious diseases, diabetes, neural and visual sciences, urban and community health and musculoskeletal disease.

The University Health Network (UHN) is committed to training the next generation of researchers and clinicians in cutting-edge molecular medicine. UHN is fully affiliated with the University of Toronto and provides positions for nearly 1500 trainees in research.

UHN's technology transfer department, the Office of Technology Commercialization & Development (TDC), helps our researchers create and commercialize intellectual property through licensing agreements or the formation of a company and establish new partnerships with industry.

I invite you to read more about us, to learn about our capabilities, to explore potential partnerships with us and to contact us for more information about anything you read on this site.

Christopher J. Paige, PhD
Executive Vice President, Science and Research, UHN
Ronald Buick Chair in Cancer Research, Princess Margaret Cancer Centre
Professor, Departments of Immunology and Medical Biophysics, University of Toronto
 
About Dr. Paige

Dr. Paige is an internationally recognized leader in the area of lymphocyte development and antibody formation, with an active research program in training the immune system to recognize cancer cells. His original research is published in leading scientific journals including Nature, Science, Cell and the Journal of Experimental Medicine.

He earned a Ph.D. in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He was a Member of the Basel Institute for Immunology in Switzerland (1980-1987) before joining the Ontario Cancer Institute as a Senior Scientist in 1987.

In 1990, Dr. Paige became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1998, he returned to the Ontario Cancer Institute to assume the role of Vice President, Research and, subsequently assumed his current position of Executive Vice President, Science and Research at the UHN, which comprises four hospitals: Toronto Rehab, Toronto General Hospital, Toronto Western Hospital and Princess Margaret Cancer Centre.

A Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto, Dr. Paige is an active educator in the undergraduate, graduate and postgraduate programs of the University.

He has served on the Research Advisory Boards of the National Cancer Institute and the Arthritis Society of Canada. He is the past Chairman of the Board of the Biotechnology Commercialization Centre, which helped establish a Biotechnology Incubator in Toronto and past Chairman of BioDiscovery Toronto, a consortium of 12 Toronto-based hospitals and universities engaged in the commercialization of research discoveries. He also serves on the Boards of the Terry Fox Research Institute, The Princess Margaret Cancer Foundation, the Toronto General & Western Hospital Foundation, the Arthritis Research Foundation, the Council of Ontario Research Directors, Research Canada, the Ontario Institute for Cancer Research and the Ontario Health Research Alliance. Dr. Paige is also a co-founder and the Chairman of the Board of GEMMA Biotechnology. Its purpose is to discover and commercially develop biological response modifiers which influence the course of human disease. He was the founder and co-Director of the Shanghai-Toronto Institute for Health Science (STI), a partnership between the Shanghai Institute of Health Sciences, the Shanghai Institute of Organic Chemistry and UHN. UHN currently maintains laboratories in the Zhangjiang High Technology Park in Shanghai.

Read more about Dr. Paige's research interests.


   
 
 
 
Home Researchers Facilities Support Services Programs Commercialization Ethics News About UHN Institutes OCI Techna TGRI TRI TWRI hyperlink to UHNResearchnews Facebook page hyperlink to UHNResearch Twitter feed